Gilead Sciences, Inc. (GILD)
Price:
120.41 USD
( - -2.80 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
AstraZeneca PLC
VALUE SCORE:
7
2nd position
Biogen Inc.
VALUE SCORE:
8
The best
Sanofi
VALUE SCORE:
8
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
NEWS
Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-13 05:52:55Ameriprise Financial Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 397.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,748,403 shares of the biopharmaceutical company's stock after buying an additional 5,392,191 shares during
AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-13 05:52:50AQR Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 32.5% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,470,838 shares of the biopharmaceutical company's stock after buying an additional 606,168 shares during
Investors Buy Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD)
defenseworld.net
2025-12-13 01:14:44Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) was the target of some unusual options trading on Friday. Stock investors acquired 165,669 call options on the company. This is an increase of 1,115% compared to the average volume of 13,634 call options. Analyst Upgrades and Downgrades GILD has been the topic of several research analyst
Gilead, Arcus scrap late-stage trial of cancer drug combo
reuters.com
2025-12-12 08:36:24Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit.
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
zacks.com
2025-12-11 10:40:59Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ariel Investments LLC Has $40.90 Million Position in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-10 03:31:21Ariel Investments LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 14.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 368,861 shares of the biopharmaceutical company's stock after selling 61,563 shares during the period. Ariel Investments LLC's holdings in Gilead
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
businesswire.com
2025-12-09 08:30:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
businesswire.com
2025-12-07 08:00:00SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT). Results were shared from the combined analysis of four-year data from the la.
Gilead Sciences, Inc. $GILD Position Decreased by Brown Advisory Inc.
defenseworld.net
2025-12-07 04:24:56Brown Advisory Inc. reduced its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 6.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,539 shares of the biopharmaceutical company's stock after selling 17,362 shares during the quarter. Brown Advisory Inc.'s holdings
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
businesswire.com
2025-12-06 14:00:00SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These new.
Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
businesswire.com
2025-12-06 14:00:00SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Both KITE-753 and.
Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC
defenseworld.net
2025-12-05 05:54:42CW Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 309.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 100,734 shares of the biopharmaceutical company's stock after purchasing an additional 76,119 shares during
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
zacks.com
2025-12-04 10:01:15Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Groupe la Francaise Has $3.92 Million Stake in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-04 04:43:07Groupe la Francaise grew its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 1,467.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,490 shares of the biopharmaceutical company's stock after acquiring an additional 33,226 shares during the period. Groupe la
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-03 15:13:35Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-12-03 01:23:29Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-13 05:52:55Ameriprise Financial Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 397.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,748,403 shares of the biopharmaceutical company's stock after buying an additional 5,392,191 shares during
AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-13 05:52:50AQR Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 32.5% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,470,838 shares of the biopharmaceutical company's stock after buying an additional 606,168 shares during
Investors Buy Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD)
defenseworld.net
2025-12-13 01:14:44Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) was the target of some unusual options trading on Friday. Stock investors acquired 165,669 call options on the company. This is an increase of 1,115% compared to the average volume of 13,634 call options. Analyst Upgrades and Downgrades GILD has been the topic of several research analyst
Gilead, Arcus scrap late-stage trial of cancer drug combo
reuters.com
2025-12-12 08:36:24Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit.
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
zacks.com
2025-12-11 10:40:59Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ariel Investments LLC Has $40.90 Million Position in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-10 03:31:21Ariel Investments LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 14.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 368,861 shares of the biopharmaceutical company's stock after selling 61,563 shares during the period. Ariel Investments LLC's holdings in Gilead
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
businesswire.com
2025-12-09 08:30:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
businesswire.com
2025-12-07 08:00:00SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT). Results were shared from the combined analysis of four-year data from the la.
Gilead Sciences, Inc. $GILD Position Decreased by Brown Advisory Inc.
defenseworld.net
2025-12-07 04:24:56Brown Advisory Inc. reduced its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 6.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,539 shares of the biopharmaceutical company's stock after selling 17,362 shares during the quarter. Brown Advisory Inc.'s holdings
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
businesswire.com
2025-12-06 14:00:00SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These new.
Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
businesswire.com
2025-12-06 14:00:00SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Both KITE-753 and.
Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC
defenseworld.net
2025-12-05 05:54:42CW Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 309.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 100,734 shares of the biopharmaceutical company's stock after purchasing an additional 76,119 shares during
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
zacks.com
2025-12-04 10:01:15Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Groupe la Francaise Has $3.92 Million Stake in Gilead Sciences, Inc. $GILD
defenseworld.net
2025-12-04 04:43:07Groupe la Francaise grew its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 1,467.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,490 shares of the biopharmaceutical company's stock after acquiring an additional 33,226 shares during the period. Groupe la
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-03 15:13:35Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-12-03 01:23:29Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript